cannabis market research
Linkedin

• United Kingdom · free market report · October 2026

All the intelligence you need to enter the UK medical cannabis market, and to make the most of it once you’re in.

Our 44-page report follows what patients actually received — volume, value, potency, price and who supplied it — read line by line from the NHSBSA’s own dispensing records. It’s free.

England only
The NHSBSA record covers England alone and is under-reported, so it undershoots the UK market, probably by a wide margin. Read every figure here as a floor. How we handle it →
Get the free report →
See what's inside ↓
Counted, not estimated
1.77m
items of medical cannabis dispensed in England in 2025, six times the 2023 volume
44k2021
124k2022
283k2023
669k2024
1.77m2025
Items dispensed by year · NHSBSA, England onlyA floor, not the UK total
1.77m
items dispensed in England, 2025
£157m
at August 2026 list prices
+165%
items, 2025 on 2024
30 t
flower imported into the UK, 2025
1,009
SKUs dispensed in the year

Imports cover the whole UK. Everything else is England only — read it as a floor.

• The problem

A patient estimate can’t tell you what was dispensed. The dispensing record can.

You can find guesses at how many people in the UK take medical cannabis. What you won’t find in them is what those patients received, at what strength and price, or who supplied it. The report reads the answer from 394,090 NHSBSA dispensing records, resolves every line to a product, and says plainly that the record covers England only and undercounts the UK market.

1
Counted from the record, line by line
Two freedom-of-information releases, January 2019 to February 2026, combined into one series that reconciles exactly to the NHSBSA’s annual totals.
2
Resolved to the product
Free-text names matched to a 1,192-SKU index carrying format, strength, origin, grower and dated list price.
3
Tested before it is published
Every cut is re-run on a hold-out. Importer and distributor history failed that test, so the report leaves it out.
Read as a floor
England only, and it undershoots the UK market.
20–25%
a conservative uplift to reach a total-UK view
~£200m
the 2025 UK market at list prices, on that view
The NHSBSA release covers prescriptions dispensed in England. Wales, Scotland, Northern Ireland and the Crown Dependencies are outside it, and pharmacies submit it by hand, so some dispensing never reaches it. Levels are floors; shares and trends need no adjustment.

• Free — what your email unlocks

The full 44-page report, with every value labelled and every source named.

One form, and the PDF comes straight to your inbox. Seven chapters, in the order you would size up any market, and what to watch next.

01 · Free
The market and who reaches it
Chapters 01–02 · pages 4–11
✓Items and value every quarter since 2021, and the total-UK view
✓Peak flower, and the extracts taking the ground it gives up
✓The monthly clinic leaderboard, September 2025 to August 2026
02 · Free
The formulary and the brands
Chapters 03–04 · pages 12–24
✓Launches doubling for a second year, and outrunning exits six to one
✓Brand-group shares every year since 2021, with items in each segment
✓Curaleaf’s format moat, and who leads flower, oils, vapes and oral solids
03 · Free
Supply, price and what’s in the jar
Chapters 05–07 · pages 25–44
✓Imports by exporting country, and how Canada went direct
✓The weighted gram, and like-for-like list-price cuts by tier and THC band
✓Live resin and rosin, from nothing to a third of cartridges
Get the free report →

• What the report shows

The market doubled every year, and five brand groups now share what one used to hold.

Five numbers the report opens with, all read from England’s dispensing record, which undercounts the UK market. Below them, extracts from each chapter.

+165%
items dispensed, 2025 on 2024
548 → 1,009
SKUs dispensed in the year
−35 pts
Curaleaf brands’ share of items since 2023
+615%
vape cartridges in a year
−5.5%
average listed flower price, Oct 2025 → Aug 2026
The market · chapter 01, pages 4–7

Items have more than doubled every year since 2021.

Quarterly growth has not dropped below 13% since 2022 and averaged 25% a quarter, to 1.77 million items in 2025. Counting the other nations and missing submissions, the report puts the whole UK near £200m in 2025 and heading for about £400m in 2026.

Items dispensed in England, by year
0500k1m1.5m2m44k2021124k2022283k2023669k20241.77m2025

Items rose 165% in 2025, after +183%, +128% and +136% in the three years before. The fourth quarter alone dispensed 617,284 items.

NHSBSA FOI_03941 and FOI-03965 · England only · report p.5

Value dispensed in England, £m at list prices
£0m£50m£100m£150m£200m£6.6m2021£15m2022£31m2023£69m2024£157m2025

Value reached £157m in England but rose slower than items: the average item fell from £194 to £84 as 10 g packs and single vape cartridges took over. Imports agree with a UK total near £200m: 30.1 t × £6.70/g.

Items × August 2026 list prices, constant across years · NHSBSA, England only · report p.6

Brands · chapter 04, pages 18–24

Curaleaf’s brands fell from 61% of items to 26%, and three challengers built a five-group market.

Montu, Cantourage and 4C Labs went from 4% of items to 34% between 2023 and 2025, while Curaleaf’s own items still rose from 284k to 468k. A top five holding two thirds is still concentrated, now across five groups instead of one.

Share of items, % — Curaleaf brands and the five largest brand groups
0%25%50%75%100%67%26%20212022202320242025Curaleaf brandsFive largest brand groups

Curaleaf fell from 61% to 26% while its own items rose 2.7-fold. The brand groups needed to reach 80% of items went from 4 to 10; counted brand by brand, from 5 to 22.

Brand group = brands under one owner; Cantourage’s 28 imported brands as one · NHSBSA, England only · report p.19

Curaleaf brands’ share of each format, 2025
Flower items21%Oil items62%Oral-solid pieces99%

Curaleaf’s moat is formats: a fifth of flower items, but three fifths of oils and 99% of oral solids. By weight its flower share is 26%, because it sells larger packs. Aurora took 30% of vape THC from 20% of cartridges.

Items for flower and oils, pieces for oral solids · NHSBSA, England only · report p.22

Brands dispensing at least one item in 2025, by format
Flower107Oils20Vapes11Pastilles1

Flower went from 14 brands in 2021 to 107. Oils are the one format losing brands, while vapes and pastilles, thin all through 2025, are where 2026’s new entrants are landing.

Brands with at least one dispensed item in the year · NHSBSA, England only · report p.21

13 routes from grower to pharmacy, September 2026
Hover or tap a route. The percentage is its share of 2025 items where the dispensing record can attribute one; the full map in the report carries every grower, importer, brand, clinic and pharmacy.
Vertically integratedClinic-ledImport or manufacturing platformBrand owner or distributorIntegrating 2025–26
Curaleaf26.4%CuraleafVertically integratedGrowersTerra Verde (PT), Northern Green (CA), Medalchemy (ES)Clinic · pharmacyCuraleaf Clinic · Curaleaf Pharmacy2025 items26.4% of all items dispensedAurora bid, Aug 2026Lyphe · Tilray0.9%Lyphe · TilrayVertically integratedGrowersTilray Cantanhede (PT), GroVida (PT), ECS Botanics (AU)Clinic · pharmacyLyphe Clinic · Lyphe Dispensary2025 items0.9% of all items dispensedTilray bought Lyphe, Apr 2026Wellford1.8%WellfordVertically integratedGrowersAqualitas (CA) and partner growersClinic · pharmacyWellford Clinics · Newgrove2025 items1.8% of all items dispensedMontu12.2%MontuClinic-ledGrowersLittle Green Pharma (DK), ABcann (CA), other Canadian LPsClinic · pharmacyAlternaleaf · Montu Pharmacy2025 items12.2% of all items dispensedReleaf5.2%ReleafClinic-ledGrowersGlass Pharms (UK), Somaí (PT)Clinic · pharmacyReleaf · Releaf Dispensary2025 items5.2% of all items dispensedMamedica1.1%MamedicaClinic-ledGrowersCheers · Medz (CA), Miracle Valley (CA), Somaí, Glass PharmsClinic · pharmacyMamedica · Mamedica Dispensary2025 items1.1% of all items dispensedAurora6.4%AuroraIntegrating 2025–26GrowersAurora Canada, Safari Flower (CA), Aurora Nordic (DK)Clinic · pharmacyHAP Pharma (bought Aug 2026)2025 items6.4% of all items dispensedBought Internode and HAP Pharma, Aug 2026IPS PharmaIPS PharmaImport or manufacturing platformGrowersPharmaCann (MK), Aurora · Tilray, Northern Leaf (JE)Clinic · pharmacyIntegro · IPS PharmacyGrow1.4%GrowBrand owner or distributorGrowersPharmaCann (MK), SafriCanna (ZA), HollyMood (TH)Clinic · pharmacyAuravia · Grow pharmacy2025 items1.4% of all items dispensedBought Avida, Jul 2025; now in a CVACantourage11.1%CantourageImport or manufacturing platformGrowersLot420 · Green Karat (CA), Portocanna (PT) and othersClinic · pharmacyCantourage Clinic · Cedarwood2025 items11.1% of all items dispensedHilltop LeafHilltop LeafImport or manufacturing platformGrowersLittle Green Pharma (DK), Aurora resin carts (CA), ECS (AU)Clinic · pharmacyOpen market4C Labs · Xeal10.9%4C Labs · XealBrand owner or distributorGrowersOrganigram, AgMedica, Rubicon (1964), MG Health (CA)Clinic · pharmacySupplies Mamedica · Xeal Dispensary2025 items10.9% of all items dispensedHologramHologramImport or manufacturing platformGrowersSomaí (PT), Thai flower (TH)Clinic · pharmacyOpen marketOwnership event, Sep 2026
Supply and origin · chapter 05, pages 25–28

Imports doubled to 30 tonnes, and Canada now ships most of them direct.

Canadian flower went from 2,578 kg to 17,067 kg in a year as producers bypassed EU processors. Counting re-exports through Portugal, Canada supplies an estimated 70–80% of UK volume.

Flower imported against flower dispensed, tonnes
0102030402.00.720218.61.920226.94.0202315.08.8202430.120.32025Imported into the UKDispensed in England

Imports doubled to 30.1 tonnes in 2025 against 20.3 t dispensed in England, and Canada shipped 57% of them, up from 17%. At the fourth-quarter run-rate, 2026 lands near 47 t.

Home Office import FOIs (UK, by exporting country) against NHSBSA dispensing (England only) · report p.26

Flower dispensed in 2025, by country of cultivation
Canada49.0%Portugal23.7%United Kingdom6.8%South Africa3.5%North Macedonia2.2%Spain1.7%

Canada grows half of UK flower on 78 farms, and no single Canadian farm holds even a tenth of it. The largest grower overall holds 21.5%, and the ten largest hold 60%.

Grower = cultivating licence holder; 3% of 2025 flower has no resolved grower · NHSBSA, England only · report p.27

Patients and access · chapter 02, pages 8–11

Alternaleaf passed Releaf in May 2026, and the clinic leaderboard is still moving.

Alternaleaf went from 163k monthly visits to 504k in eleven months. Clinic traffic leads the dispensing record rather than mirrors it, and fewer than 1% of eligible specialists prescribe at all.

Share of tracked UK clinic web traffic, %
0%20%40%60%27%21%20%Sep 25Feb 26May 26Aug 26ReleafAlternaleafCuraleaf Clinic

Releaf gave up 29.3 points in eleven months and Alternaleaf, Montu’s UK clinic, took 14.7 of them. It has led since May 2026.

SimilarWeb estimates compiled monthly; Oct–Nov 2025 not captured · report p.11

Prescribers writing at least one dispensed item
01002003001720193720209820211162022164202320620242532025

From 17 clinicians in 2019 to 253, and the five largest fell from 81% of items to 24%. But one prescriber ID was still linked to 188,000 items: the record counts who signs repeats, often a pharmacist, not who decides.

Prescriber of record on the dispensed item, pseudonymised · NHSBSA FOI-03965, England only · report p.9

The product · chapters 03, 06 and 07, pages 12–17 and 32–43

The product moved faster than the price.

Flower peaked at 84.9% of items in 2024 and vapes are taking the ground it gives up. The formulary lists 904 SKUs, but only 480 were in stock in August 2026.

3.0% → 8.9%
of items are vapes, 2024 Q4 to 2025 Q4
33%
of cartridges live resin or rosin, from zero
16% → 58%
of flower volume in 10 g packs, 2022 to 2025
545
SKUs dispensed for the first time in 2025
Volume-weighted THC of dispensed flower, %
0.0%10.0%20.0%30.0%24.9%22 Q123 Q124 Q125 Q4Average THC

From 18.4% in 2022 to 24.9% at the end of 2025, rising every single quarter. It looks level, but Canadian flower already averages 26.3% here and mature markets sit near 30%. 29% of volume is 28% THC or more.

Declared THC on the prescription, falling back to the product index · NHSBSA, England only · report p.34

Share of items held by the ten biggest SKUs
0%20%40%60%80%66%202159%202251%202325%202417%2025

In 2021 ten products were most of the market. In 2025 the biggest single SKU held under 3%, and SKUs ranked 101 and below took 39% of items.

SKUs ranked inside each year · NHSBSA, England only · report p.16

Price · chapter 05, pages 28–31

Prices are easing slowly, and the cuts are landing on premium flower.

75 of 400 flower SKUs listed at both dates were cut. Patients traded up to a £6.73 gram in 2024 and came back down to £6.59, as the £6–7 middle shrank from 29% of volume to 21%.

Like-for-like list-price change by THC band, Oct 2025 → Aug 2026
Under 20% THC−0.1%20–24%−2.1%24–28%−4.9%28% and over−7.7%0%

Across 400 flower SKUs priced at both dates, lists fell 3.5%. The cuts landed at the top: −7.7% at 28% THC and over, almost nothing under 20%.

Same SKUs at two formulary dates, isolating price changes · report p.31

Price per milligram of THC, 2025, by origin
South Africa2.50pCanada2.59pNorth Macedonia2.67pPortugal2.80pSpain2.95pUnited Kingdom3.67p

Canadian flower costs more per gram than Portuguese — £6.84 against £6.06 — but at 26.4% THC it is cheaper per milligram. UK-grown, at £7.83 a gram and 21.4% THC, is the dearest THC on the shelf.

Weighted price per gram ÷ (weighted THC% × 10 mg) · August 2026 list prices · England · report p.29

What to watch · closing page, page 44

Three things will decide the UK’s next year.

Each one shows up in the next FOI release, formulary snapshot or import return, and each would move the numbers above by more than a rounding error.

01
Scale
Does the market almost double again?

If 2026 follows 2025, the UK approaches 150,000 patients and about £400m.

● Tracked in Decide · Every NHSBSA release
02
Diversity
Where does the next wave of growth come from?

Watch whether vapes and pastilles keep taking share from flower, turning a flower market into a multi-format one.

● Tracked in Decide · Every formulary snapshot
03
Price
Maturation, or stability?

Australia and Germany compressed as supply caught up. The UK has eased 3.5% like for like in ten months.

● Tracked in Decide · Every dated list price
Free report
Every chart above is an extract. The report carries the full series, chapter by chapter, with every value labelled and every source named.
Get the free report →

• Look inside

Seven chapters, what to watch next, and the question each one answers for you.

Pick a chapter to see what is in it and the number it opens with.

Chapter 01 · pages 4–7
The market
How big is it, how fast is it growing, and in which formats?
  • ✓Items and value every quarter since 2021, with every value labelled
  • ✓Why value lags items, and why the total UK market is already close to £200m
  • ✓Peak flower, and the extracts taking the ground it gives up
£157m
dispensed in England in 2025, at list prices
Get the full chapter →
Chapter 02 · pages 8–11
Patients and access
Who prescribes, and which clinics are winning the patient?
  • ✓From 17 prescribers to 253, and why the record counts who signs repeats, not who decides
  • ✓The monthly clinic leaderboard, September 2025 to August 2026
  • ✓Where the 29 share points Releaf gave up actually went
253
active prescribers in 2025, from 17 in 2019
Get the full chapter →
Chapter 03 · pages 12–17
The formulary
How many products are there, how fast do they turn over, and what is in stock?
  • ✓SKUs dispensed every quarter by format, from 78 in 2021 to 717
  • ✓Launches doubling for a second year, and outrunning exits six to one
  • ✓The formulary in 2026: 904 listed, about half of it in stock
545
SKUs dispensed for the first time in 2025
Get the full chapter →
Chapter 04 · pages 18–24
Brands
Which brand groups move the volume, and how did the challengers grow?
  • ✓Brand-group shares every year since 2021, with items in each segment
  • ✓Curaleaf’s format moat, and who leads flower, oils, vapes and oral solids
  • ✓Ranges, pack sizes and price per gram for the twelve largest groups
61% → 26%
Curaleaf brands’ share of items, 2023 to 2025
Get the full chapter →
Chapter 05 · pages 25–31
Supply, origin and price
Where does the flower come from, and what do patients pay?
  • ✓Imports by exporting country, and how Canada went direct
  • ✓Flower grower by grower, and price per milligram of THC by origin
  • ✓The weighted gram, and like-for-like list-price cuts by tier and THC band
−7.7%
list-price cut at 28% THC and over
Get the full chapter →
Chapter 06 · pages 32–37
Flower
What is in the jar — potency, pack size, cultivar and treatment?
  • ✓Kilograms dispensed by THC band, quarter by quarter
  • ✓Why potency looks level at 25% but is not at a ceiling
  • ✓The 10 g pack, indica–sativa labels and irradiation
24.9%
weighted flower THC, 2025 Q4, from 18.4%
Get the full chapter →
Chapter 07 · pages 38–43
Extracts
What is happening in vapes, oils and oral solids?
  • ✓Vapes from 6.4k to 54.6k items a quarter, and cartridges from 58% to 73% THC
  • ✓Live resin and rosin, from nothing to a third of cartridges
  • ✓Oils turning into a THC format, and a one-supplier oral-solid category
33%
of vape cartridges are live resin or rosin
Get the full chapter →
Closing page · page 44
What to watch
Which three things will decide the UK’s next year?
  • ✓Scale: does the market almost double again?
  • ✓Diversity: where the next wave of growth comes from
  • ✓Price: maturation, or stability?
~£400m
where 2026 is heading if it follows 2025
Get the full report →

• Free · 44 pages · October 2026

Take the whole UK market with you.

Everything on this page comes from the report, and the report goes much further.

  • ✓The market in nine numbers
    Items, value, prescribers, SKUs, brands and the leader’s share
  • ✓Brand groups, owner by owner
    Shares since 2021, format moats, ranges and pack sizes
  • ✓Thirteen supply routes, mapped
    Grower, importer, brand, clinic and pharmacy for each
  • ✓The monthly clinic leaderboard
    Five largest clinics, September 2025 to August 2026
  • ✓Price, potency and pack size
    Constant-price series and like-for-like list-price cuts
  • ✓What to watch in 2026
    Scale, product diversity and whether prices hold
Free download · PDF
UK Medical Cannabis Market Report, October 2026
Tell us where to send it and the PDF comes straight to your inbox.

If the form does not appear, email info@cannamonitor.com and we will send the report over.

• How we built it

England only and under-reported, so every figure is a floor.

You should know the limits of the data before you rely on it. The report measures the market from the dispensing record itself, tests every cut against a hold-out, and leaves out what fails.

☷
Two FOI releases
394,090 records and 3.13 million items, January 2019 to February 2026, combined by union rather than deduplicated.
◉
Every line resolved
49,614 matched aliases and 4,478 strength-aware decisions join each line to a 1,192-SKU product index.
✓
Validated by hold-out
Each measure is recomputed from a partial snapshot, and item totals reconcile exactly to the NHSBSA’s annual counts.
■
Published or withheld
Cuts that fail the hold-out are left out. Importer and distributor history failed, so there is none.
How complete the record is — NHSBSA, England only
100%
Items, quantity, pack size, date
Reported directly
99.3% of items
SKU identity after standardisation
Everything product-level
99.1% of items
List price per g, ml or piece
Value, price bands, price and potency
100% of flower volume
Declared THC and CBD
Potency bands and weighted averages
92% of 2025 flower
Country of cultivation
Origin and grower views, 2025 only
Withheld
Importer and distributor
Withheld as a time series

• Track record

We called it in 2024. The 2026 data confirmed it.

Anyone can describe a market after it moves. We have published the UK numbers from the dispensing record since 2024, and every call below is dated and still online. Pick one to see what we wrote and what the 2026 data shows.

5calls published in 2024
5confirmed by the 2026 data
1.77mitems in 2025, against the 1 million we called
We wrote · Feb & Oct 2024

The market will double again in 2024, and could pass 1 million items by 2025. Earlier, in February 2024, we put 2023 at around 200,000 items.

Read the original →
↓
What the 2026 data shows

2024 more than doubled to 669k, and 2025 reached 1.77 million, 77% above the million we called. 2023 came in at 283,000.

✓ Confirmed and beaten
05001000150020002002832023100017752025What we forecast (k items)What was dispensed (k items)

NHSBSA, England only · report p.5

We wrote · Oct 2024

Flower over 24% THC went from 3% of prescriptions in 2022 to 22% in 2023. We called it an increasingly potency-focused market.

Read the original →
↓
What the 2026 data shows

Weighted flower THC rose every single quarter, from 18.4% in 2022 to 24.9% at the end of 2025, and 29% of volume is now 28% THC or stronger.

✓ Confirmed
0.0%10.0%20.0%30.0%24.9%22 Q123 Q124 Q125 Q4Average THC of dispensed flower, %

NHSBSA, England only · report p.34

We wrote · Oct 2024

Three-quarters of supply was European, but Canadian products were quickly gaining ground, led by demand for high-THC flower.

Read the original →
↓
What the 2026 data shows

Canada shipped 57% of UK flower imports in 2025, up from 17% a year earlier, as producers bypassed EU processors. Counting re-exports through Portugal, it supplies an estimated 70–80% of UK volume.

✓ Confirmed
0%20%40%60%17%202457%2025

Home Office import FOIs, whole UK · report p.26

We wrote · Oct 2024

Vapes, capsules and pastilles held about 1% of prescriptions, with room to grow as prescribers and patients got used to them.

Read the original →
↓
What the 2026 data shows

Vape cartridges grew 7.1 times in 2025 and vapes went from 3.0% of items to 8.9% in a year. Live resin and rosin went from nothing to a third of cartridges.

✓ Confirmed
050k100k150k19.9k2024142k2025

NHSBSA, England only · report p.39

We wrote · Nov 2024

Our 2024 report named Curaleaf the leader in flower, oils and capsules.

Get the 2026 edition instead →
↓
What the 2026 data shows

Curaleaf is still the largest brand group. Its share fell from 61% to 26% as the market crowded in, but its own items rose 2.7-fold in two years, and it holds 62% of oil items and 99% of oral solids.

✓ Confirmed
0k200k400k600k69k2022173k2023284k2024468k2025

Items dispensed, NHSBSA, England only · report p.19 and p.22

• Published intelligence on the UK

Everything we have published on the UK, newest first.

The report is the latest piece in a record that goes back to 2024. Each article below is built from the same dispensing data and carries the number it opened with.

Free · 44 pages
1.77m
items dispensed in England in 2025
United Kingdom · Oct 2026
UK Medical Cannabis Market Report 2026
Seven chapters on volume, brands, supply, price and formats, every value labelled and every source named
Get it free →
Hash and rosin reach the international medical shelf
United Kingdom · 22 Jul 2026
Hash and rosin reach the international medical shelf
The UK listed its first medical hash in May 2026, and carries 3 in-stock concentrates against 98 in Ontario
Read →
The UK market doubles again, and flower loses share
United Kingdom · 14 May 2026
The UK market doubles again, and flower loses share
Vapes went from 2% to 5% of dispensed items between 2024 and H1 2025, the first crack in a flower monoculture
Read →
Canada ships 276 tonnes in 2025, and the UK is its next unlock
Canada → UK · 8 Apr 2026
Canada ships 276 tonnes in 2025, and the UK is its next unlock
C$40m of Canadian flower went to the UK in 2025, up 267%, the fastest growth of any established corridor
Read →
High-THC flower leads a market in full bloom
United Kingdom · 7 Oct 2024
High-THC flower leads a market in full bloom
Flower over 24% THC went from 3% to 22% of flower prescriptions in a single year
Read →
Clinics drive exponential growth in the UK market
United Kingdom · 16 Feb 2024
Clinics drive exponential growth in the UK market
Items nearly tripled in 2022 as private clinics took over patient onboarding
Read →
See all insights →

• Free report or Decide

The report is dated October 2026. Decide keeps moving.

Every number in the report is a live dataset in Decide, updated as each FOI release, formulary snapshot and clinic month lands.

What you get
Free report
🔒 Included in Decide (paid)
Market size and growth
✓2021 to 2025, as published in October 2026
✓Refreshed with each NHSBSA release
Products on the shelf
✓Shelf structure, launches and the biggest SKUs
✓Every SKU by format, brand group, strength and quarter
Brands
✓Brand-group shares, format moats and ranges, to 2025
✓Every brand and owner, refreshed as ownership deals close
Prices
✓Two formulary dates, compared like for like
✓Every formulary snapshot, dated
Clinics
✓The five largest, September 2025 to August 2026
✓Every tracked UK clinic, month by month
Supply chain
✓Thirteen routes from grower to pharmacy
✓Grower, importer and distributor per SKU, with ownership events as they happen
Other markets
✓The UK only
✓120+ other markets on the same basis
Price
✓Free
✓€1,420 a year
What neither can tell you. Dispensing in Wales, Scotland and Northern Ireland: the NHSBSA release is England only. What a pharmacy actually charged: we hold list prices. Prescriptions per clinic: visits measure reach, not scripts.
Also in Decide · beyond the UK
The UK sits in the same workspace as every other market, company, deal and trial we track.
125+countries

Benchmark UK momentum against Germany, Australia, Spain, Czechia, Poland and Switzerland, on the same basis.

1,050+company profiles

Financials, deals, trials, licences and news, joined up for every operator in the UK chain.

640+M&A and funding deals

Normalised to USD, source-linked, and tied to buyer, target and market. See the tracker.

2,300+clinical trials

Matched to the product and sponsor behind each. See the pipeline.

270+regulatory briefs

A living layer per market, tied to the country and the companies it affects.

Get the free report →
Explore Decide →

• Questions

What people ask us about the UK report.

Is the report free?
Yes. Leave your work email and we send the full 44-page PDF straight to your inbox.
Where does the data come from?
From the NHSBSA’s own dispensing records, obtained through two freedom-of-information releases (FOI_03941 and FOI-03965) covering private prescriptions for unlicensed cannabis-based medicines dispensed in England from January 2019 to February 2026. Import volumes come from Home Office FOIs, prices from dated formulary snapshots and clinic traffic from SimilarWeb estimates we compile every month.
Does it cover the whole UK?
No, and we say so on every page. The release covers England only, and dispensing submissions are manual, so some are missing — the record undershoots the UK market, probably by a wide margin. Treat every figure as a floor: adding 20–25% to any level is a conservative way to reach a total-UK view. Shares and trends are not affected.
Why count items rather than patients?
Because items are what the record actually contains. A prescription item is one product dispensed once — a 10 g jar or a single vape cartridge. Patient counts in the report come from Prohibition Partners and are attributed as such.
Why does the report stop at 2025?
January and February 2026 are still being filled in by late submissions, so reading them now would understate the market. The report reads 2026 through the formulary, list prices and imports instead, and the dispensing series updates in Decide as the records land.
What is the difference between the report and Decide?
The report is a snapshot, dated October 2026. Decide is where the same data keeps moving — every FOI release, formulary snapshot and clinic month as it arrives, alongside the same reconciled data for more than 120 other markets.

Everything on this page is live in Decide. Take it into your UK plan, with 120+ other markets beside it.

Start with the free report. When you need the numbers to keep moving, Decide is where they live.

Get the free report →
Explore Decide →